Example: Heart Attack

Clinical Trials on Scleroderma, Diffuse

Total 15 results

  • NCT04837131
    Recruiting
    A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients
    Conditions: Systemic Sclerosis, Scleroderma, Diffuse Systemic Sclerosis, Diffuse Scleroderma, Diffuse Cutaneous Systemic Sclerosis, Diffuse Cutaneous Scleroderma, Progressive Systemic Sclerosis, Progressive Scleroderma, Scleroderma, Systemic, Scleroderma, Diffuse, Scleroderma;Progressive, Systemic Sclerosis, Diffuse, Systemic; Sclerosis, Progressive, Scleroderma of Lung, Scleroderma With Pulmonary Involvement, Systemic Sclerosis Pulmonary, Systemic Sclerosis With Lung Involvement, Interstitial Lung Disease, Pulmonary Fibrosis Interstitial
  • NCT02682511
    Recruiting
    Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
    Conditions: Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic, Skin Diseases, Connective Tissue Diseases, Pathologic Processes, Autoimmune Diseases
  • NCT03222492
    Recruiting
    Brentuximab Vedotin for Systemic Sclerosis
    Conditions: Diffuse Cutaneous Systemic Sclerosis, Scleroderma, dcSSc
  • NCT04464434
    Recruiting
    Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis
    Conditions: Systemic Sclerosis, Systemic Scleroses, Diffuse, Scleroderma, Scleroderma, Diffuse, Autologous Stem Cell Transplantation, Cyclophosphamide, Mycophenolate Mofetil, Treatment Strategy
  • NCT04647890
    Not yet recruiting
    Effects of FT011 in Systemic Sclerosis
    Conditions: Scleroderma, Systemic, Scleroderma, Diffuse, Sclerosis, Systemic
  • NCT03831438
    Active, not recruiting
    Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis
    Conditions: Scleroderma, Diffuse
  • NCT02298777
    Recruiting
    Metabolomic Analysis of Systemic Sclerosis
    Conditions: Scleroderma (Limited and Diffuse), Undifferentiated Connective Tissue Disease, Raynaud Disease, Vascular Disease, Healthy Control Subjects
  • NCT02503644
    Completed
    Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis
    Conditions: Scleroderma, Diffuse, Diffuse Cutaneous Systemic Sclerosis
  • NCT01785056
    Unknown status
    IVIG Treatment in Systemic Sclerosis
    Conditions: Systemic Sclerosis, Diffuse Scleroderma
  • NCT01538719
    Completed
    IL1-TRAP, Rilonacept, in Systemic Sclerosis
    Conditions: Scleroderma, Systemic Sclerosis, Diffuse Scleroderma, Diffuse Systemic Sclerosis
  • NCT00442611
    Completed
    A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)
    Conditions: Scleroderma, Diffuse, Scleroderma, Systemic
  • NCT02374320
    Terminated
    Exparel as a Nerve Block for Severe Hand Pain
    Conditions: CREST Syndrome, Peripheral Vascular Disease, Raynaud Disease, Scleroderma, Diffuse
  • NCT01347008
    Completed
    Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis
    Conditions: Scleroderma, Systemic, Scleroderma, Diffuse, Scleroderma, Limited, Raynaud Phenomenon
  • NCT01881529
    Completed
    A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma
    Conditions: Limited Scleroderma, Diffuse Scleroderma
  • NCT00428883
    Unknown status
    High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis
    Conditions: Scleroderma, Diffuse
Medical Conditions
Sponsors and Collaborators
Drug Interventions
Conditions
Rare Diseases
Drug Interventions
Dietary Supplements
Sponsor/Collaborators
Locations